Qiyuan Zhou

981 citations
20 papers · 774 indexed · h-index 14
Topics
Pulmonary Hypertension Research and Treatments (9 papers)Cancer, Hypoxia, and Metabolism (6 papers)MicroRNA in disease regulation (4 papers)

In The Last Decade

Qiyuan Zhou

18 papers receiving 766 citations

Peers

Qiyuan Zhou
Comparison fields: 5 of 77
  • Molecular Biology 457
  • Pulmonary and Respiratory Medicine 365
  • Cancer Research 280
  • Surgery 83
  • Oncology 80
Replace Nam-Gyun Kim with:
Nam-Gyun Kim South Korea
Valérie Nadeau Canada
Sachindra Raj Joshi United States
Jun Yi China
Astrid Weiß Germany
Pin-I Chen United States
Chongxiu Sun United States
Gamal Andre Banat Germany
B.A. McKeon United States
Huan Jin China
Qiyuan Zhou relative to Nam-Gyun Kim South Korea Nam-Gyun Kim's profile →
Citations per field
00.5×4.7×
Nam-Gyun Kim · 1×
Citations per year

Countries citing papers authored by Qiyuan Zhou

Since Specialization
Citations

This map shows the geographic impact of Qiyuan Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiyuan Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiyuan Zhou more than expected).

Fields of papers citing papers by Qiyuan Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiyuan Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiyuan Zhou. The network helps show where Qiyuan Zhou may publish in the future.

Co-authorship network of co-authors of Qiyuan Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Qiyuan Zhou. A scholar is included among the top collaborators of Qiyuan Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiyuan Zhou. Qiyuan Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 7
3 14
4 0
5 118
6 30
7 21
8 30
9 13
10 0
11 49
12 5
13 58
14 16
15 59
16 14
17 77
18 48
19 21
20 193

About Qiyuan Zhou

Qiyuan Zhou is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 20 papers that have together received 774 indexed citations. Recurring topics across this work include Pulmonary Hypertension Research and Treatments (9 papers), Cancer, Hypoxia, and Metabolism (6 papers) and MicroRNA in disease regulation (4 papers). The work is most often cited by research in Cancer Research (280 citations), Pulmonary and Respiratory Medicine (365 citations) and Molecular Biology (457 citations). Qiyuan Zhou has collaborated with scholars based in United States, China and Australia. Frequent co-authors include Guofei Zhou, Tianji Chen, J. Usha Raj, Jingbo Dai, Jacob I. Sznajder, Laura A. Dada, John Varga, Haiyang Tang, Aileen Kelly and Minghua Wu. Their work appears in journals such as Nature Communications, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026